Cloudflare's IPO last week continues to trade well.
80 deals created $44.8 billion of market value for newly public US biotechs (Image: Genomics Law Report).
Co-founder Jonathan Lim, MD, was CEO of Ignyta, which was acquired by Roche in February 2018 for $1.7 billion.
Company chart and information is provided by TradingView based on 15-minute-delayed data.
Guardant Health, based in Redwood City, California, provides cancer blood tests and analytics for clinical and research use, and the firm maintains research partnerships with large biopharmaceutical companies. The company offers Guardant 360, a blood-based (liquid biopsy) test for treatment selection in advanced stage cancer, and Guardant Omni, a broader gene panel for immuno-oncology research. The company's pipeline includes Lunar-1, for cancer recurrence detection in survivors, and Lunar-2, a liquid biopsy for early detection of cancer in higher-risk individuals, with an initial focus on colorectal cancer. Additionally, Guardant offers research development services. The United States accounts for 90% of total revenue, and other markets the remaining 10%.
| Website: | www.guardanthealth.com |
| Email: | investors@guardanthealth.com |
| Main Phone: | +1 855 698-8887 |
| Address: | 505 Penobscot Drive |
| State: | CA |
| City / Town: | Redwood City |
| Country: | US |
| Postal Code: | 94063 |
| Exchange: | NGS |
| CEO: | Helmy Eltoukhy |
| Employees: | 864 |
| NAICS: | Medical Laboratories(621511) |
Cloudflare's IPO last week continues to trade well.
80 deals created $44.8 billion of market value for newly public US biotechs (Image: Genomics Law Report).
Co-founder Jonathan Lim, MD, was CEO of Ignyta, which was acquired by Roche in February 2018 for $1.7 billion.
| Last Price N/A | Change $ N/A | Change % N/A | Tick N/A |
| Bid N/A | Bid Size N/A | Ask N/A | Ask Size N/A |
| Open N/A | High N/A | Low N/A | Prev Close N/A |
| Last Trade | Volume N/A | 52 Wk Hi N/A | 52 Wk Low N/A |
| Market Cap N/A | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares N/A | EPS (TTM) N/A | PE Ratio N/A | Exchange N/A |
© 2022 Equities News | Equities.com, Inc.
* All dates and time are being displayed in Eastern Standard Time (EST).
